# Orbital Therapeutics

> Orbital Therapeutics raised a $270M Series A in 2023 to build next-generation RNA medicine platforms.

## Why it is interesting

One of 2023’s largest biotech Series A rounds — ARCH led the Cambridge RNA platform play with a16z Bio + Health as an initial backer.

## Profile

- **Stage:** acquired
- **Status:** acquired
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Apr 2023): $270M led by ARCH Venture Partners; a16z Bio + Health participated (Businesswire)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/orbital-therapeutics